EP
SNDX icon

Eversept Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

Eversept Partners’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$67.4M Sell
2,885,622
-428,786
-13% -$9.32M 3.55% 8
2025
Q4 		$69.6M Sell
3,314,408
-152,906
-4% -$2.67M 3.51% 7
2025
Q3 		$53.3M Sell
3,467,314
-598,041
-15% -$7.83M 3.68% 6
2025
Q2 		$38.1M Sell
4,065,355
-146,915
-3% -$1.62M 3.5% 8
2025
Q1 		$51.7M Buy
4,212,270
+3,868,870
+1,127% +$54.6M 5.26% 5
2024
Q4 		$4.54M Sell
343,400
-3,761,913
-92% -$64.4M 0.4% 42
2024
Q3 		$79M Buy
4,105,313
+491,682
+14% +$10.2M 5.41% 6
2024
Q2 		$74.2M Buy
3,613,631
+480,518
+15% +$10.1M 5.08% 7
2024
Q1 		$74.6M Sell
3,133,113
-250,131
-7% -$5.58M 4.97% 7
2023
Q4 		$73.1M Buy
3,383,244
+786,999
+30% +$12.1M 6.42% 3
2023
Q3 		$37.7M Buy
2,596,245
+406,513
+19% +$7.69M 3.19% 8
2023
Q2 		$45.8M Sell
2,189,732
-19,325
-0.9% -$402K 3.83% 8
2023
Q1 		$46.7M Buy
2,209,057
+588,344
+36% +$14.6M 3.25% 8
2022
Q4 		$41.2M Buy
1,620,713
+409,279
+34% +$9.55M 3.61% 9
2022
Q3 		$29.1M Buy
1,211,434
+217,072
+22% +$4.87M 2.52% 11
2022
Q2 		$19.1M Buy
+994,362
New +$16.6M 1.36% 22

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eversept Partners's SNDX Position: Q1 2026 in Review

Eversept Partners reduced its Syndax Pharmaceuticals (SNDX) stake by 13% in Q1 2026, selling an estimated $9.32M and leaving 2,885,622 shares worth $67.4M. The position accounts for 3.55% of the portfolio, ranked #8.

Eversept Partners first reported a position in SNDX in Q2 2022 and has held it in 16 quarters since. The position peaked at $79M in Q3 2024. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Eversept Partners held 2,885,622 shares of Syndax Pharmaceuticals worth $67.4M as of Q1 2026.
  • Eversept Partners sold 428,786 Syndax Pharmaceuticals shares in Q1 2026, an estimated $9.32M.
  • Syndax Pharmaceuticals made up 3.55% of Eversept Partners's portfolio in Q1 2026, its #8 holding.
  • Eversept Partners first reported a position in Syndax Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • Eversept Partners's Syndax Pharmaceuticals position peaked at $79M in Q3 2024.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.